

SURVEILLANCE REPORT

Hepatitis C

Annual Epidemiological Report for 2023

Key facts

- In 2023, 28 622 cases of hepatitis C were reported in 29 EU/EEA countries, corresponding to a crude rate of 7.4 cases per 100 000 population.
- Of the cases reported, 4.9% were acute, 34.1% chronic, and 53.8% were unknown. Seven percent could not be classified due to an incompatible data format.
- Hepatitis C was more commonly reported among men than women, with a male-to-female ratio of 1.7:1. The most affected age group among males and females was 35–44 years (6.1 cases per 100 000 population).
- The most common transmission mode was injecting drug use, which accounted for 54.4% of acute cases and 68.2% of chronic cases with complete information on transmission route.
- The interpretation of hepatitis C notification data across countries remains problematic, with differences in surveillance systems, various testing/screening policies, and difficulties in differentiating acute, chronic and reinfection cases. Improvements in data quality and a revision of the current case definition are needed to better describe the progress towards elimination goals.

Introduction

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) [1]. The virus enters the body through infected blood or other bodily fluids. The transmission can occur via the use of contaminated needles or medical equipment, contaminated blood transfusions, unsafe sex with an infected person, and vertically from a mother to her child during the pregnancy or the delivery [1].

Hepatitis C is a major public health threat worldwide, with an estimated 50 million people living with HCV infection in 2024, an incidence of 1 million new cases per year, and 244 000 attributable deaths in 2022 [2]. The disease burden is also high in the European Union and European Economic Area (EU/EEA), with an estimated 1.8 million people living with HCV (0.5%) [3].

Methods

This report is based on 2023 data retrieved from The European Surveillance System (TESSy) on 5 February 2025.

For a detailed description of the methods used to produce this report, refer to the Methods chapter of the 'Introduction to the ECDC Annual Epidemiological Report' [4].

An overview of national surveillance systems is available on the ECDC website [5].

A subset of the data used for this report is available through ECDC's online 'Surveillance atlas of infectious diseases' [6].

EU/EEA countries reported data on newly diagnosed cases of hepatitis C to ECDC according to the EU 2018 case definition of acute and chronic hepatitis C or other definitions (Table 1) [7].

Suggested citation: European Centre for Disease Prevention and Control. Hepatitis C. In: ECDC. Annual epidemiological report for 2023. Stockholm: ECDC; 2025.

Stockholm, April 2025

© European Centre for Disease Prevention and Control, 2025. Reproduction is authorised, provided the source is acknowledged.

Table 1. Case definition for acute and chronic hepatitis C

| Stage | Definition |
|---------|---|
| Acute | Recent HCV seroconversion (prior negative test for hepatitis C in last 12 months) |
| | or |
| | Detection of hepatitis C virus nucleic acid (HCV RNA) or hepatitis C virus core antigen (HCV-core) in serum/plasma and no detection of hepatitis C virus antibody (negative result) |
| Chronic | Detection of hepatitis C virus nucleic acid (HCV RNA) or hepatitis C core antigen (HCV-core) in serum/plasma in two samples taken at least 12 months apart [*] |
| Unknown | Any newly diagnosed case which cannot be classified in accordance with the above description of acute or chronic infection |

*: in the event that the case was not notified the first time.

Surveillance systems across EU/EEA countries are heterogeneous. Twenty-one countries submitted national data for 2023 based on the 2012 or 2018 EU case definitions, four countries used the 2008 EU case definition, and four countries used national case definitions.

All reported cases were included in the analysis regardless of which case definition was used. Data collected represent confirmed cases. Hungary only submitted data on acute cases of hepatitis C. Two countries (Belgium and Bulgaria) only submitted aggregate data and did not differentiate between stages of infection. No data have been reported by the United Kingdom (UK) since 2019 due to its withdrawal from the EU on 1 February 2020.

Annual notification rates were calculated per 100 000 population for countries with comprehensive surveillance systems using Eurostat population data [8].

Epidemiology

For 2023, 29 EU/EEA countries reported 28 622 cases of HCV infection, corresponding to a crude rate of 7.4 cases per 100 000 population. No data were reported from France. Of all cases, 1 405 (4.9%) were reported as acute, 9 748 (34.1%) as chronic, 15 394 (53.8%) as 'unknown' (Table 2), and 2 075 cases (7.2%) could not be classified because of an incompatible data format.

In countries reporting consistently, the overall rate decreased from 7.7 per 100 000 in 2014 progressively to 6.6 in 2019. In 2020 and 2021, a substantial decline was observed, with the rate between 4.6 and 4.7 per 100 000, followed by an increase to 8.0 per 100 000 in 2023 (Figure 1).

Country-specific rates ranged from 0.1 cases per 100 000 population in Italy to 71.3 cases per 100 000 population in Lithuania (Table 2, Figure 2).

Twenty countries were able to provide data on acute cases (Table 2). The rate of reported acute cases was 0.4 per 100 000 population, ranging from 0 in Croatia, Greece, Italy, Poland, Portugal, Romania and Slovenia to 1.7 per 100 000 in Sweden.

Twenty countries submitted data on chronic infections. The notification rate of chronic cases was 3.1 cases per 100 000 population, ranging from 0 in Italy, Poland, Portugal, and Romania to 70.8 in Lithuania. The rate of cases classified as unknown ranged from 0 cases per 100 000 population in Cyprus, Greece, and Italy to 54.6 in Luxembourg. Overall notification rates were mostly higher in northern and eastern European countries (Figure 2).

Table 2. Number of reported hepatitis C cases and rates per 100 000 population by country and year,2019-2023⁺

| | 2019 | | 2020 | | 2021 | | 2022 | | 2023 | | | | | | | |
|---------------------------------|--------|------|--------|------|--------|------|--------|------|--------|------|--------|------|---------|------|---------|------|
| Country | All | | Acute | | Chronic | | Unknown | |
| | Number | Rate | Number | Rate | Number | Rate |
| Austria | 1 120 | 12.6 | 843 | 9.5 | 858 | 9.6 | 912 | 10.2 | 918 | 10.1 | 71 | 0.8 | 301 | 3.3 | 546 | 6.0 |
| Belgium | 1 209 | NRC | 701 | NRC | 468 | NRC | 695 | NRC | 854 | NRC | NDR | NRC | NDR | NRC | NDR | NRC |
| Bulgaria | 88 | 1.3 | 44 | 0.7 | 25 | 0.4 | 51 | 0.8 | 80 | 1.2 | NDR | NRC | NDR | NRC | NDR | NRC |
| Croatia | 209 | 5.3 | 95 | 2.4 | 112 | 2.9 | 42 | 1.1 | 55 | 1.4 | 0 | 0.0 | 5 | 0.1 | 50 | 1.3 |
| Cyprus | 27 | 3.1 | 9 | 1.0 | 7 | 0.8 | 13 | 1.4 | 16 | 1.7 | NDR | NRC | 16 | 1.7 | 0 | 0.0 |
| Czechia | 1 138 | 10.7 | 771 | 7.2 | 764 | 7.3 | 977 | 9.3 | 1 141 | 10.5 | NDR | NRC | NDR | NRC | NDR | NRC |
| Denmark | 122 | 2.1 | 161 | 2.8 | 149 | 2.6 | 205 | 3.5 | 202 | 3.4 | 6 | 0.1 | 196 | 3.3 | NDR | NRC |
| Estonia | 141 | 10.6 | 135 | 10.2 | 134 | 10.1 | 119 | 8.9 | 121 | 8.9 | 8 | 0.6 | 113 | 8.3 | NDR | NRC |
| Finland | 1 180 | 21.4 | 1 143 | 20.7 | 1 063 | 19.2 | 1 148 | 20.7 | 1 125 | 20.2 | NDR | NRC | NDR | NRC | 1 125 | 20.2 |
| France | NDR | NRC | NDR | NRC | NDR | NRC |
| Germany | 5 964 | 7.2 | 4 538 | 5.5 | 4 771 | 5.7 | 8 023 | 9.6 | 10 448 | 12.4 | 859 | 1.0 | 3 988 | 4.7 | 5 601 | 6.6 |
| Greece | 119 | 1.1 | 54 | 0.5 | 43 | 0.4 | 104 | 1.0 | 244 | 2.3 | 2 | 0.0 | 242 | 2.3 | 0 | 0.0 |
| Hungary | NDR | NRC | NDR | NRC | NDR | NRC | NDR | NRC | 18 | 0.2 | 18 | 0.2 | NDR | NRC | NDR | NRC |
| Iceland | 111 | 31.1 | 88 | 24.2 | 66 | 17.9 | 122 | 32.4 | 107 | 27.6 | NDR | NRC | NDR | NRC | 107 | 27.6 |
| Ireland | 468 | 9.5 | 327 | 6.6 | 419 | 8.4 | 477 | 9.4 | 536 | 10.2 | 9 | 0.2 | 89 | 1.7 | 438 | 8.3 |
| Italy | 188 | 0.3 | 48 | 0.1 | 22 | 0.0 | 49 | 0.1 | 33 | 0.1 | 2 | 0.0 | 6 | 0.0 | 25 | 0.0 |
| Latvia | 1 404 | 73.1 | 1 059 | 55.5 | 948 | 50.1 | 881 | 47.0 | 797 | 42.3 | 24 | 1.3 | 773 | 41.1 | NDR | NRC |
| Liechtenstein | NDR | NRC | NDR | NRC | 4 | 10.2 | 2 | 5.1 | 2 | 5.0 | NDR | NRC | 1 | 2.5 | 1 | 2.5 |
| Lithuania | NDR | NRC | 73 | 2.6 | 59 | 2.1 | 847 | 30.2 | 2 038 | 71.3 | 15 | 0.5 | 2 023 | 70.8 | NDR | NRC |
| Luxembourg | 29 | 4.7 | 526 | 84.0 | 368 | 58.0 | 411 | 63.7 | 361 | 54.6 | NDR | NRC | NDR | NRC | 361 | 54.6 |
| Malta | 31 | 6.3 | 26 | 5.1 | 32 | 6.2 | 61 | 11.7 | 136 | 25.1 | 6 | 1.1 | 87 | 16.1 | 43 | 7.9 |
| Netherlands | 738 | 4.3 | 428 | 2.5 | 474 | 2.7 | 450 | 2.6 | 431 | 2.4 | 35 | 0.2 | NDR | NRC | 396 | 2.2 |
| Norway | 661 | 12.4 | 469 | 8.7 | 382 | 7.1 | 475 | 8.8 | 632 | 11.5 | NDR | NRC | NDR | NRC | 632 | 11.5 |
| Poland | 3 343 | 8.8 | 955 | 2.5 | 1 244 | 3.4 | 2 527 | 6.9 | 3 267 | 8.9 | 12 | 0.0 | 0 | 0.0 | 3 255 | 8.9 |
| Portugal | 220 | 2.1 | 147 | 1.4 | 166 | 1.6 | 202 | 2.0 | 197 | 1.9 | 2 | 0.0 | 2 | 0.0 | 193 | 1.8 |
| Romania | 22 | 0.1 | NDR | NRC | NDR | NRC | 1 234 | 6.5 | 931 | 4.9 | 9 | 0.0 | 0 | 0.0 | 922 | 4.8 |
| Slovakia | 247 | 4.5 | 204 | 3.7 | 183 | 3.4 | 325 | 6.0 | 578 | 10.6 | 29 | 0.5 | 549 | 10.1 | NDR | NRC |
| Slovenia | 70 | 3.4 | 96 | 4.6 | 95 | 4.5 | 113 | 5.4 | 135 | 6.4 | 1 | 0.0 | 74 | 3.5 | 60 | 2.8 |
| Spain | 1 396 | 3.0 | 699 | 1.5 | 1 266 | 2.7 | 2 142 | 4.5 | 2 226 | 4.6 | 120 | 0.2 | 602 | 1.3 | 1 504 | 3.1 |
| Sweden | 1 397 | 13.7 | 1 023 | 9.9 | 1 131 | 10.9 | 1 138 | 10.9 | 993 | 9.4 | 177 | 1.7 | 681 | 6.5 | 135 | 1.3 |
| Total EU/EEA (30 countries) | 21 642 | 5.7 | 14 662 | 4.1 | 15 253 | 4.3 | 23 745 | 6.4 | 28 622 | 7.4 | 1 405 | 0.4 | 9 748 | 3.1 | 15 394 | 4.7 |
| United Kingdom ^{II} | 17 738 | 26.6 | NDR | NRC | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| EU/EEA (31 countries) | 39 380 | 8.9 | 14 662 | 4.1 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |

Sources: country reports; NDR: no data reported; NRC: no rate calculated; †: data presented by date of diagnosis; I: includes cases reported by countries as acute, chronic or unknown using differentiation criteria. Countries reporting aggregate data only (Bulgaria and Belgium) were not able to classify cases into acute, chronic, or unknown; 'All cases' not displayed for countries that only report acute cases. II: No data from 2020 onwards were reported by the United Kingdom, due to its withdrawal from the EU on 31 January 2020.





Sources: country reports from Austria, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, Germany, Greece, Iceland, Ireland, Italy, Latvia, Luxembourg, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, and Sweden.



Figure 2. Notification rate of hepatitis C cases per 100 000 population by country*, EU/EEA, 2023

*: Countries with comprehensive surveillance systems.

Sources: country reports from Austria, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, Germany, Greece, Iceland, Ireland, Italy, Latvia, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.

Age and gender

In 2023, 17 801 cases were reported in males (9.8 cases per 100 000 population) and 10 770 in females (5.8 cases per 100 000 population), excluding countries that only reported acute cases. The male-to-female ratio was 1.7. Rates were higher among males than females for all age categories between 20 and 64 years (Figure 3). The most affected age groups were males aged between 35 and 44 years old (14.3 cases per 100 000 population) and females aged 35 to 64 years (6.1 cases per 100 000 population). People under 25 years represent 3.9 percent of all reported cases.





Sources: Country reports from Austria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, Germany, Greece, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.

Route of transmission

Data regarding the most likely route of transmission of hepatitis C were complete for only 33.8% of all cases in 2023, 44.7% of acute, 34.7%% of chronic cases, and 33.2% in cases with unknown disease status.

The most reported route of transmission across all disease categories was injecting drug use, accounting for 46.7% of cases with known transmission route. The percentage of transmission attributable to injecting drug use was 54.4% among acute cases, 68.2% among chronic cases, and 29.7% among unknown cases (Figure 4). The second most reported route of transmission among acute cases was nosocomial infection (12.2%) followed by sex between men (8.8%) and non-occupational injuries (8.0%). Nosocomial transmission was reported in 40.0% of unknown cases.

Figure 4. Transmission category of hepatitis C cases¹ by acute and chronic disease status, EU/EEA, 2023



Proportion of cases (%)

1: Cases with known transmission status; *: 'Nosocomial transmission' includes hospitals, nursing homes, psychiatric institutions, and dental clinics. This category refers mainly to patients exposed through healthcare settings, distinct from 'needle-stick and other occupational exposure', which refers to staff; **: 'Non-occupational injuries' include needle-sticks that occur outside a healthcare setting, bites, tattoos and piercings; ***: 'Needle-stick and other occupational exposure' refers to occupational injuries.

Sources: Acute reports from Austria, Croatia, Cyprus, Denmark, Estonia, Germany, Greece, Hungary, Ireland, Italy, Latvia, the Netherlands, Poland, Portugal, Romania, Slovakia, Spain, and Sweden; Chronic reports from Austria, Croatia, Denmark, Estonia, Germany, Ireland, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.

Importation status

In 2023, 29 countries provided data for 11 396 cases (39.8%) on whether a case was considered imported from outside the reporting country or acquired in the country itself. Of those cases, 2 564 (22.5%) were reported as imported.

Discussion

The surveillance data show that the number of newly diagnosed hepatitis C notifications remains substantial across the EU/EEA. In 2023, information on the stage of infection is missing for the majority of notifications, probably due to limited information on previous hepatitis C test results, highlighting the difficulties encountered by countries in applying the current EU case definition [7].

From 2014 to 2019, the notification rate decreased progressively, and between 2020 and 2021 this rate dropped substantially compared to previous years, reflecting the disruption in testing services observed during the COVID-19 pandemic [9-13]. Since 2021, the increasing number of notifications might be partly explained by the recovery of health systems after the pandemic, the development of various testing initiatives (general population screening, testing of different population groups), changes in surveillance, and an increase in migrant populations in some countries [13-20]. In some countries, these increases seem mainly driven by the effort undertaken to reduce the number of undiagnosed cases through testing/screening interventions increasing the notification of chronic infections that were likely not recently infected [14, 20].

The burden of hepatitis C in the EU/EEA remains high, with an estimated 1.8 million people (0.5%) infected with HCV [3]. While the incidence of new infections declined in many European countries due to implementation of prevention strategies, including harm reduction programmes, infection prevention and control (IPC) interventions in healthcare setting and treatments using direct-acting antiviral (DAA) drugs for diagnosed cases, modelling studies suggest that the attributable mortality will remain substantial [3, 21-25].

The geographical variations across EU/EEA countries reflect differences in testing policies, reporting practices and underlying epidemiological differences [22, 14, 15, 18]. Several northern and western European countries with extensive testing programmes and countries conducting testing initiatives such as Lithuania reported the highest notification rates, whereas some of the lowest rates were in eastern and south-eastern countries, where underlying prevalence is highest [3, 15]. This discrepancy highlights the need for additional information, such as testing practices, number of people tested, positivity rates, reinfections and up-to-date prevalence estimates to better interpret hepatitis C surveillance data [22, 26].

Despite existing prevention programmes, injecting drug use remains the main route of transmission among reported chronic cases. Estimates of hepatitis C prevalence in the EU/EEA highlight the high prevalences of hepatitis C among people who inject drugs (PWID) in most countries [3, 27]. Harm reduction programmes and, more recently, treatment with DAA drugs may have contributed to reducing transmission in this population. However, evidence of ongoing transmission emphasises the need for more comprehensive and integrated harm reduction interventions tailored for the most vulnerable populations [21, 27].

Nosocomial transmission and transmission among men who have sex with men (MSM) are other frequent routes of transmission. Reports of hepatitis C infections among MSM, and especially HIV-positive people, in several European countries resulted in scaling up specific prevention and control responses [28, 29]. Although nosocomial transmission remains uncommon in most European countries, the high proportion of nosocomial transmission among cases reported without information on the duration of the hepatitis C infection is problematic [30]. This might be due to insufficient connection between health events management systems and hepatitis C surveillance systems in some countries. Effort to integrate these data sources will help to better describe the epidemiological situations.

Public health implications

The first 'Global Health Sector Strategy on Viral Hepatitis' aimed at eliminating viral hepatitis as a public health threat [31] by reducing the incidence of chronic infections by 90% and the associated mortality by 65% by 2030. Achieving these targets will require a significant scaling up of key interventions, including preventing transmission among PWID [32], and increasing testing with linkage to care and treatment [33].

To achieve the elimination goals as defined in the Global Strategy, robust epidemiological information is essential to plan and monitor effective prevention and control programmes. Surveillance data alone do not provide a clear epidemiological picture and should be analysed carefully alongside information on local screening policies and practices, testing and positivity rates, and prevalence data. ECDC is working closely with EU/EEA countries to develop complementary data systems, such as the collection of monitoring data, ongoing prevalence estimates, and sentinel surveillance.

Further improvements to the quality of hepatitis C surveillance data are crucial to increase data utility. A reflection on the standards for surveillance including a pragmatic revision of the surveillance objectives and the epidemiological outputs is needed. The current EU case definition should be reviewed by ECDC together with the European Hepatitis Network taking into consideration the missing information on hepatitis C stage of infection in

most notifications and the issue of reinfections. Complementary and alternative sources of data should be better integrated to prevent a fragmented description of the situation. The possibility to automatically retrieve hepatitis C data through electronic health records should be further explored to reduce the underestimation of the diagnosed cases. Beyond the improvement of the data collection and processing approaches, gathering testing data alongside the notified cases is pivotal, as interpreting the trends in notifications requires a good understanding of the positivity rates by population and area.

Despite the limitations of routine surveillance for hepatitis C, the data clearly indicate that a high proportion of reported cases are attributed to injecting drug use, highlighting the importance of harm reduction measures. Evidence-based interventions are crucial to address the risks attributable to injecting drug use, and best practices implemented in some countries should be widely promoted and shared across the EU/EEA [32, 34]. Ongoing nosocomial transmission and transmission among MSM in the region emphasise the need to implement targeted and comprehensive public health programmes tailored to the local epidemiology.

References

- 1. World Health Organization (WHO). Hepatitis C. Geneva: WHO; 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
- World Health Organization (WHO). Global hepatitis report 2024: action for access in low- and middleincome countries. Geneva: World Health Organization; 2024. Available at: <u>https://www.who.int/publications/i/item/9789240091672</u>
- 3. Thomadakis C, Gountas I, Duffell E, Gountas K, Bluemel B, Seyler T, et al. Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis. Lancet Reg Health Eur. 2024 Jan;36:100792.
- 4. European Centre for Disease Prevention and Control. Introduction to the Annual Epidemiological Report. In: ECDC. Annual epidemiological report [Internet]. Stockholm: ECDC; 2022. Available at: <u>https://www.ecdc.europa.eu/en/surveillance-and-disease-data/annual-epidemiological-reports/introduction-annual</u>
- 5. European Centre for Disease Prevention and Control. Surveillance systems overview [Internet]. Stockholm: ECDC; 2022. Available at: <u>https://www.ecdc.europa.eu/en/publications-data/surveillance-systems-overview-2022</u>.
- 6. Surveillance atlas of infectious diseases [Internet]. ECDC. 2024. Available at: https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=27
- 7. European Commission. Commission implementing decision (EU) 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions. Brussels: European Commission; 2018. Available at: <u>https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32018D0945</u>
- 8. Eurostat. Eurostat database. Brussels: European Union; 2022. Available at: <u>https://ec.europa.eu/eurostat/</u>
- 9. Kaufman HW, Bull-Otterson L, Meyer WA, 3rd, Huang X, Doshani M, Thompson WW, et al. Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic. Am J Prev Med. 2021 Sep;61(3):369-76.
- Simões D, Stengaard AR, Combs L, Raben D. Impact of the COVID-19 pandemic on testing services for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region, March to August 2020. Euro Surveill. 2020 Nov;25(47)
- 11. Kondili LA, Andreoni M, Aghemo A, Mastroianni CM, Merolla R, Gallinaro V, et al. Forecasting the long-term impact of COVID-19 on hepatitis C elimination plans in Italy: A mathematical modelling approach. Liver Int. 2023 Dec;43(12):2615-24.
- 12. Gamkrelidze A, Handanagic S, Shadaker S, Turdziladze A, Tsereteli M, Getia V, et al. The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia. Public Health. 2022 Apr;205:182-6.
- 13. Zakrzewska K, Stępień MM, Rosińska M. Hepatitis C in Poland in 2021. Przegl Epidemiol. 2023;77(2):220-32.
- 14. Hüppe D, Wedemeyer H, Cornberg M. Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany. J Hepatol. 2023 Nov 3
- 15. Ciupkeviciene E, Petkeviciene J, Sumskiene J, Dragunas G, Dabravalskis S, Kreivenaite E, et al. Hepatitis C Virus Epidemiology in Lithuania: Situation before Introduction of the National Screening Programme. Viruses. 2022 May 30;14(6)
- Genowska A, Zarębska-Michaluk D, Strukcinskiene B, Razbadauskas A, Moniuszko-Malinowska A, Jurgaitis J, et al. Changing Epidemiological Patterns of Infection and Mortality Due to Hepatitis C Virus in Poland. J Clin Med. 2023 Jun 8;12(12)
- 17. Demant J, Krohn-Dehli L, Van der Veen J, Øvrehus A, Lazarus JV, Weis N. Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark. Int J Drug Policy. 2023 Nov;121:104185.
- 18. Dröse S, Øvrehus ALH, Holm DK, Røge BT, Christensen PB. Hepatitis C screening and linkage to care with a mobile clinic in Southern Denmark. Int J Drug Policy. 2023 Nov;121:104180.
- 19. Institutul National de Sanatate Publica. Analiza epidemiologică descriptivă a cazurilor de hepatită virală B și C intrate în sistemul național de supraveghere în anul 2023. Bucuresti: Institutul National de Sanatate Publica; 2024.
- 20. The Health Protection Surveillance Centre (HPSC). Epidemiology of hepatitis C in Ireland Trends from 2004 to Q1 2024. Dublin: HPSC; 2024.
- 21. Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415.

- 22. Sharrock KC, Noori T, Axelsson M, Buti M, Diaz A, Fursa O, et al. Monitoring progress towards elimination of hepatitis B and C in the EU/EEA. PLOS Glob Public Health. 2022;2(8):e0000841.
- 23. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013 Mar;58(3):593-608.
- 24. Dultz G, Zeuzem S. Hepatitis C Virus: A European Perspective. Gastroenterol Clin North Am. 2015 Dec;44(4):807-24.
- 25. Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):332-42.
- 26. European Centre for Disease Prevention and Control. Monitoring of responses to the hepatitis B and C epidemics in EU/EEA countries 2020 data. Stockholm: ECDC; 2022. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/Monitoring-responses-to-hepatitis-B-and-C-epidemics-2020-data.pdf
- 27. European Union Drugs Agency. European Drug Report 2024: Trends and Developments, Lisbon: EUDA; 2024. Available at: <u>https://www.emcdda.europa.eu/publications/european-drug-report/2023_en</u>
- 28. Hoornenborg E, Achterbergh RCA, Schim van der Loeff MF, Davidovich U, Hogewoning A, de Vries HJC, et al. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. Aids. 2017 Jul 17;31(11):1603-10.
- 29. Castry M, Cousien A, Supervie V, Velter A, Ghosn J, Paltiel AD, et al. Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach. Gut. 2021 Aug;70(8):1561-9.
- Singh J, Stoitsova S, Zakrzewska K, Henszel L, Rosińska M, Duffell E. Healthcare-associated hepatitis B and C transmission to patients in the EU/EEA and UK: a systematic review of reported outbreaks between 2006 and 2021. BMC Public Health. 2022 Dec 3;22(1):2260.
- 31. World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. Geneva: WHO; 2016. Available at: <u>https://www.who.int/publications/i/item/WHO-HIV-2016.06</u>
- 32. European Centre for Disease Prevention and Control (ECDC) and European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Prevention and control of infectious diseases among people who inject drugs: 2023 update. Stoclkholm: ECDC; 2023. Available at: <u>https://www.ecdc.europa.eu/en/publications-data/prevention-and-control-infectious-diseases-among-people-who-inject-drugs-2023</u>
- 33. Schwarz T, Horváth I, Fenz L, Schmutterer I, Rosian-Schikuta I, Mårdh O. Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation. Int J Drug Policy. 2022 Apr;102:103588.
- Horváth I, Mårdh O, Schwarz T. Models of good practice to enhance infectious disease care cascades among people who inject drugs: a qualitative study of interventions implemented in European settings. BMC Health Serv Res. 2023 Dec 4;23(1):1352.